https://www.nasdaq.com/press-release/adamis-pharmaceuticals-updates-comparative-pharmacology-model-data-supporting-the
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-regains-compliance-with-nasdaq-continued-listing-requirements
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-third-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-schedules-financial-results-conference-call-and-business
https://www.nasdaq.com/press-release/adamis-receives-fda-approval-for-zimhi-2021-10-18
https://www.nasdaq.com/press-release/adamis-announces-appointment-of-meera-desai-ph.d.-to-board-of-directors-2021-10-04
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-doses-first-patients-in-phase-2-3-clinical-trial-for-tempol-in
https://www.nasdaq.com/press-release/adamis-announces-appointment-of-david-c.-benedicto-as-chief-financial-officer-and
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-a-publication-with-the-human-immune-monitoring
https://www.nasdaq.com/press-release/adamis-highlights-national-institutes-of-health-nih-article-entitled-tempol%3a-a
https://www.nasdaq.com/press-release/adamis-announces-agreement-to-sell-portion-of-us-compounding-business-2021-08-04
https://www.nasdaq.com/press-release/adamis-announces-results-of-2021-annual-meeting-of-stockholders-2021-07-19
https://www.nasdaq.com/press-release/adamis-urges-stockholders-to-vote-to-reelect-the-companys-board-of-directors-at
https://www.nasdaq.com/press-release/adamis-sends-letter-to-stockholders-to-address-jerald-a.-hammanns-costly-distracting
https://www.nasdaq.com/press-release/adamis-sends-letter-to-stockholders-regarding-its-strategic-focus-on-tempol-as-a
https://www.nasdaq.com/press-release/adamis-files-definitive-proxy-statement-and-sends-letter-to-stockholders-2021-06-14
https://www.nasdaq.com/press-release/adamis-provides-update-on-clinical-trial-start-up-progress-for-tempol-in-the
https://www.nasdaq.com/press-release/adamis-provides-update-on-zimhitm-2021-06-09
https://www.nasdaq.com/press-release/adamis-highlights-national-institute-of-health-study-identifying-tempol-as-a
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-business-update-2021-06-01
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-receipt-of-deficiency-letter-from-nasdaq-2021-05-28
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-update-on-first-quarter-2021-financial-results
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-resubmits-zimhi-new-drug-application-to-fda-for-the-treatment
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-schedules-first-quarter-2021-financial-results-conference-call
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-2020-financial-results-and-business-update-2021-04
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-an-update-on-zimhitm-2021-04-12
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-tempol-reduces-lung-inflammation-in-the-covid-19
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-cleared-to-proceed-with-human-studies-of-tempol-for-the
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-strengthens-patent-portfolio-for-its-naloxone-product
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-2021-02
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-2021-01
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-2021-01-28
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-and-human-immune-monitoring-center-at-stanford-university
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-update-on-its-us-compounding-business-2021-01-26
https://www.nasdaq.com/press-release/symjepi-products-now-available-in-the-walgreens-prescription-savings-club-with-the
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-ind-submission-to-fda-for-tempol-for-the-treatment
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-describes-planned-response-to-zimhi-complete-response-letter
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-receives-a-complete-response-letter-from-the-fda-regarding-0
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-third-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-schedules-third-quarter-2020-results-conference-call-and
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-2020-09
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-2020-09-17
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-update-on-annual-meeting-of-stockholders-2020-09-03
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-update-on-annual-meeting-of-stockholders-2020-08-21
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-second-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-pre-ind-feedback-from-fda-enabling-advancement-of
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-update-on-symjepi-products-2020-07-01
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-publication-of-pharmacokinetic-model-suggesting-that
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-license-to-commercialize-tempol-a-novel
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-publication-of-pharmacokinetic-study-comparing-zimhi
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-first-quarter-2020-financial-results-and-business
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-resubmits-zimhi-new-drug-application-to-fda-2020-05-18
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-schedules-first-quarter-2020-earnings-conference-call-and
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-update-on-symjepi-products-and-announces-distribution
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-publication-demonstrating-pet-scan-results-of-higher
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-production-of-additional-drugs-by-its-us-compounding
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-receipt-of-loan-proceeds-under-paycheck-protection
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-production-of-products-by-its-subsidiary-us
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-2019-financial-results-and-business-update-2020-03
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-pricing-of-%246.7-million-registered-direct-offering
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-update-regarding-zimhi-2020-02-19
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-an-update-on-zimhi-2019-12-19
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-receives-a-complete-response-letter-from-the-fda-regarding
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-publication-of-comparative-pharmacokinetics-of
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-third-quarter-2019-financial-results-and-business
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-schedules-third-quarter-2019-earnings-conference-call-and
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-provides-regulatory-update-for-its-higher-dose-naloxone-pre
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-presentation-of-zimhi-data-at-ihv-scientific-meeting
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-commercial-partnership-with-emerge-health-for
https://www.nasdaq.com/press-release/adamis-pharmaceuticals-announces-presentation-pertaining-to-its-high-dose-naloxone
